|
1
|
Subclinical hypothyroidism in children and adolescents: a wide range of clinical, biochemical, and genetic factors involved.
|
J Clin Endocrinol Metab
|
2009
|
1.16
|
|
2
|
Ghrelin secretion in childhood is refractory to the inhibitory effect of feeding.
|
J Clin Endocrinol Metab
|
2004
|
0.95
|
|
3
|
Ghrelin secretion is inhibited by glucose load and insulin-induced hypoglycaemia but unaffected by glucagon and arginine in humans.
|
Clin Endocrinol (Oxf)
|
2004
|
0.92
|
|
4
|
Increased interleukin-10 in Helicobacter pylori infection could be involved in the mechanism protecting from allergy.
|
J Pediatr Gastroenterol Nutr
|
2007
|
0.85
|
|
5
|
Primary cutaneous large B-cell lymphoma of the leg: histogenetic analysis of a controversial clinicopathologic entity.
|
Hum Pathol
|
2002
|
0.82
|
|
6
|
A functional common polymorphism in the vitamin D-responsive element of the GH1 promoter contributes to isolated growth hormone deficiency.
|
J Clin Endocrinol Metab
|
2007
|
0.82
|
|
7
|
MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens.
|
Int J Biol Markers
|
2015
|
0.82
|
|
8
|
Characterization of Epstein-Barr virus genotype in AIDS-related non-Hodgkin's lymphoma.
|
AIDS Res Hum Retroviruses
|
2002
|
0.81
|
|
9
|
Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis.
|
Cardiovasc Toxicol
|
2012
|
0.79
|
|
10
|
Clarithromycin resistance of Helicobacter pylori strains isolated from children' gastric antrum and fundus as assessed by fluorescent in-situ hybridization and culture on four-sector agar plates.
|
Helicobacter
|
2008
|
0.77
|
|
11
|
Human herpesvirus type 8-associated primary lymphomatous effusion in an elderly HIV-negative patient: clinical and molecular characterization.
|
Ann Ital Med Int
|
2002
|
0.76
|
|
12
|
Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines.
|
Invest New Drugs
|
2015
|
0.76
|
|
13
|
Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study.
|
Anticancer Drugs
|
2016
|
0.75
|